AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18058479
Drug: Amlodipine maleate
RxNorm normalized name: Amlodipine Maleate
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine maleate 10 mg
Trial: 18058479
Drug: Amlodipine besylate
RxNorm normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine besylate 10 mg (Norvasc)
Trial: 16118338
Drug: 17beta-estradiol (E2)
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 17beta-estradiol (E2) supplementation (2 mg/d for 8 days)
Trial: 2680790
Drug: 3-drug therapy
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-drug therapy (Adriablastine, Cisplatin, Cyclophosphamide)
Trial: 2680790
Drug: Two-drug chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-drug chemotherapy without Cisplatin
Trial: 9118661
Drug: Cisapride (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (60 mg initially followed by two doses of 30 mg at 8-hr intervals)
Trial: 2949285
Drug: Cefoxitin 2
RxNorm normalized name: cefoxitin 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin 2 g administered once
Trial: 2949285
Drug: Piperacillin 4
RxNorm normalized name: piperacillin 4000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin 4 g administered once
Trial: 26349552
Drug: Vancomycin plus
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin plus flucloxacillin (combination group)
Trial: 26349552
Drug: Vancomycin (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (standard therapy group)
Trial: 26349552
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (vancomycin)
Trial: 22441222
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (sham treatment with disconnected HVES equipment)
Trial: 18420939
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg prednisolone daily in addition to disease-modifying anti-rheumatic drugs
Trial: 17585662
Drug: Sequential acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential acupuncture method
Trial: 16304265
Drug: Lung volume
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung volume reduction surgery (LVRS) and optimal medical therapy
Trial: 16304265
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy only
Trial: 9031992
Drug: Zolpidem 10
RxNorm normalized name: zolpidem 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 10 mg daily for 27 nights (preceded by 2 nights of placebo and followed by 3 nights of placebo)
Trial: 9031992
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 nights before and 3 nights after zolpidem administration)
Trial: 1523530
Drug: Lactobacillus suppository
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus suppository
Trial: 31645180
Drug: Group reminiscence
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group reminiscence therapy (two 30- to 45-minute sessions weekly for 12 weeks)
Trial: 31645180
Drug: Conventional drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drug treatments and routine daily care (Control)
Trial: 26678518
Drug: Higher-dose media
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose media buy (3 times standard dose)
Trial: 26678518
Drug: Standard-dose media
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose media buy
Trial: 23920107
Drug: Specific education
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific education program on appropriate indications of intravenous lines
Trial: 18693456
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus rosiglitazone (4 mg/d)
Trial: 1330127
Drug: Short-term group
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term group therapy
Trial: 4073101
Drug: Ticarcillin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticarcillin (3 g) plus clavulanate potassium (200 mg) administered intravenously
Trial: 4073101
Drug: Piperacillin (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin (125 to 200 mg/kg per day) administered intravenously
Trial: 31024557
Drug: Poly-ICLC (1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poly-ICLC (1.4 mg subcutaneously, two consecutive daily doses)
Trial: 18197495
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant human growth hormone (rhGH) 0.15 IU/kg daily for 7 days postoperatively
Trial: 18197495
Drug: Placebo (menstruum)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (menstruum) injection daily for 7 days postoperatively
Trial: 15990570
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg daily dose of hydroxyurea
Trial: 15990570
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of hydroxyurea (900 mg and 1200 mg)
Trial: 12149667
Drug: Irbesartan (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (300 mg/day)
Trial: 10541778
Drug: Warfarin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (10 mg on day 1 and 2.5‐10 mg on days 2‐21)
Trial: 343489
Drug: Papaverine (5‐‐10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papaverine (5‐‐10 mg per kg body weight)
Trial: 30782183
Drug: Single-dose antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose antimicrobial prophylaxis (AP) with cotrimoxazole
Trial: 24257591
Drug: Daily monitoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily monitoring of traumatic symptoms and substance use behaviors using PDAs
Trial: 24257591
Drug: No daily
RxNorm normalized name: Aveeno Daily Moisturizing
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No daily monitoring assessments (only pre- and post-monitoring online assessments)
Trial: 15451221
Drug: Oral amoxicillin
RxNorm normalized name: amoxicillin Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin (n=857)
Trial: 15451221
Drug: Parenteral penicillin
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral penicillin (n=845)
Trial: 11394606
Drug: Tibial eminence
RxNorm normalized name: Eminence Bright Skin Starter Set Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibial eminence fracture treatment
Trial: 8092118
Drug: Group I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I: surgery if possible, otherwise biopsy followed by whole-brain irradiation to a total dose of 34 Gy in 4 fractions, VCR (2 mg i.v.), and BCNU (80 mg/m2 i.v.) every 6 weeks
Trial: 8092118
Drug: Group II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II: irradiation as Group I plus VP16 (75 mg/m2) every 3 weeks and BCNU (50 mg/m2 i.v.) every 6 weeks
Trial: 8092118
Drug: Group III:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group III: 60 Gy in 30 fractions to the tumor bed plus VCR (2 mg i.v.), BCNU (50 mg/m2 i.v.), and CDDP (15 mg/m2 i.v.) every 6 weeks
Trial: 2979243
Drug: High nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High nicotine cigarettes (1.91 mg)
Trial: 2979243
Drug: Low nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low nicotine cigarettes (0.17 mg)
Trial: 22545738
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CBASP and nefazodone
Trial: 19447020
Drug: Lutein (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein (12 mg/day) plus green tea extract (200 mg/day)
Trial: 17218777
Drug: 1E10 anti-idiotype
RxNorm normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1E10 anti-idiotype vaccine (2 mg of aluminum hydroxide-precipitated 1E10 MAb, four biweekly injections followed by six doses at 28-day intervals)
Trial: 17218777
Drug: 1E10 anti-idiotype
RxNorm normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1E10 anti-idiotype vaccine
Trial: 12196750
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel (EE/LNG)
Trial: 8722664
Drug: Appropriate medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appropriate medical and surgical therapy
Trial: 448786
Drug: Oxamniquine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxamniquine (15 mg/kg single oral dose)
Trial: 448786
Drug: Oxamniquine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxamniquine (15 mg b.d. for a single day)
Trial: 28219295
Drug: Pharmaceutical schemas
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical schemas (beliefs about medicines)
Trial: 26936842
Drug: Ethanol solution
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol solution
Trial: 22954403
Drug: Colistin and
RxNorm normalized name: Colistin and hydrocortisone and neomycin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin and rifampicin combination
Trial: 19944006
Drug: Sublingual specific
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual specific immunotherapy (SLIT) for children with allergic rhino-conjunctivitis and seasonal asthma for a duration of no less than three years.
Trial: 19944006
Drug: Subcutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunotherapy (SCIT) for pediatric allergic rhinitis and asthma.
Trial: 17762711
Drug: Citalopram (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (7.5 mg)
Trial: 14752635
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg oral ALA (low-dose)
Trial: 14752635
Drug: 60 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/kg oral ALA (high-dose)
Trial: 14752635
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg in two fractions 4 and 6 h before PDT
Trial: 10359882
Drug: Methylprednisolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (40 mg/1.73 m2)
Trial: 2712403
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml of 0.3 M sodium citrate solution orally 5 min before induction of anaesthesia (group C)
Trial: 2712403
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without antacids (group T)
Trial: 2560
Drug: Insulin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (0.2 U/kg b.w.)
Trial: 2560
Drug: Bromazepam (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromazepam (0.1 mg/kg b.w.)
Trial: 2560
Drug: Insulin +
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin + Bromazepam
Trial: 27533077
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy delivered via mail
Trial: 25779708
Drug: Morphine injection
RxNorm normalized name: morphine Injection
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine injection
Trial: 25779708
Drug: Morphine-midazolam solution
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Morphine-midazolam solution
Trial: 23343906
Drug: Tacrolimus (TAC)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus (TAC) 0.1 mg/kg·day with prednisone at 0.5 mg/kg·day
Trial: 23343906
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CTX) 0.5-0.75 g/m(2)·month, i.v. with prednisone at 0.8 mg/kg·day
Trial: 21078629
Drug: Transdermal 17β-oestradiol
RxNorm normalized name: 17β-oestradiol
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal 17β-oestradiol (50 µg/day)
Trial: 19797249
Drug: Fentanyl 25
RxNorm normalized name: FENTANYL 25MCG/HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 25 microg + bupivacaine 0.5% (0.8 ml) + normal saline 0.3 ml
Trial: 19797249
Drug: Sufentanil 5
RxNorm normalized name: SUFentanil 50 MCG in 1 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 5 microg + bupivacaine 0.5% (0.8 ml) + normal saline 0.7 ml
Trial: 17113886
Drug: Hydrochlorothiazide, 50
RxNorm normalized name: HydroCHLOROthiazide, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide, 50 mg/24 hr
Trial: 14760143
Drug: Individualised complete
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised complete written action plans with 2-4 action points and both inhaled corticosteroids (ICS) and oral corticosteroids (OCS)
Trial: 11313314
Drug: Peginterferon alpha2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alpha2a (180 microg once weekly for 48 weeks)
Trial: 11313314
Drug: Standard interferon
RxNorm normalized name: INTERFERON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard interferon alpha2a (thrice weekly for 48 weeks)
Trial: 9150824
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy supplementing exposure (EC)
Trial: 31290948
Drug: Short-term treatment
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term treatment of internet and computer game addiction (STICA)
Trial: 28532623
Drug: Standard sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard sequential (SS) treatment: lansoprazole 30mg b.i.d. + amoxicillin 1g b.i.d. for 5 days, followed by lansoprazole 30mg b.i.d., clarithromycin 500mg b.i.d., and metronidazole 500mg t.i.d. for 5 days
Trial: 28532623
Drug: Extended sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended sequential (ES) treatment: same as SS but for 7+7 days
Trial: 28532623
Drug: Extended sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended sequential + bismuth (ES+B) treatment: same as ES but with colloidal bismuth 600mg b.i.d. for 14 days
Trial: 25672574
Drug: Regorafenib 160
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 160 mg once daily during the first 3 weeks of each 4-week cycle
Trial: 17209788
Drug: Enamel matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enamel matrix derivative (EMD) treatment
Trial: 17209788
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no EMD treatment)
Trial: 15067859
Drug: MF59-adjuvanted hepatitis
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted hepatitis B vaccine
Trial: 15067859
Drug: Engerix-B (alum-adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engerix-B (alum-adjuvanted yeast-derived HBV vaccine)
Trial: 9054741
Drug: Integrilin (highest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrilin (highest dose)
Trial: 9728228
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) infusion of 1 mg kg‐1 h‐1 during surgery
Trial: 29185133
Drug: Resistance exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance exercise program (twice a week for 12 weeks)
Trial: 28901796
Drug: 5-mg saxagliptin
RxNorm normalized name: sAXagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-mg saxagliptin
Trial: 29350176
Drug: Prototype 4-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prototype 4-mg nicotine lozenge
Trial: 29350176
Drug: Prototype III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prototype III 4-mg nicotine lozenge
Trial: 29350176
Drug: All prototype
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All prototype 4-mg nicotine lozenges
Trial: 29350176
Drug: Prototype 4-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prototype 4-mg nicotine lozenges
Trial: 29350176
Drug: Reference 4-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference 4-mg nicotine lozenge
Trial: 21978726
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg Ferric Carboxymaltose (FCM) in two doses 5 days apart
Trial: 21978726
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg Ferric Carboxymaltose (FCM) given on day 28
Trial: 21978726
Drug: Additional 500
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional 500 mg Ferric Carboxymaltose (FCM) for those not responding to initial treatment
Trial: 8730253
Drug: lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole 30 mg b.d. for 4 weeks plus amoxycillin 1 g t.d.s. during the last 2 weeks
Trial: 8730253
Drug: lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole 30 mg once daily for 4 weeks plus classical triple therapy (tripotassium dicitratobismuthate 240 mg b.d., amoxycillin 1 g t.d.s. and tinidazole 500 mg b.d.) for the last 2 weeks
Trial: 31409606
Drug: lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole 30 mg once daily for 4 weeks
Trial: 29084737
Drug: More intensive
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More intensive antiplatelet therapy (vorapaxar and ticagrelor pooled)
Trial: 29084737
Drug: Background antiplatelet
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Background antiplatelet therapy (aspirin monotherapy)
Trial: 27401475
Drug: WelTel SMS
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WelTel SMS intervention (interactive weekly SMS 'How are you?')
Trial: 22648287
Drug: Therapeutic cervical
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic cervical facet joint injections at bilateral C5/C6 and C6/C7
Trial: 22648287
Drug: Non-injection group
RxNorm normalized name: meningococcal group B vaccine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-injection group (group N)
Trial: 20543705
Drug: DAILIES AquaComfort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAILIES AquaComfort Plus for daily disposable, daily wear
Trial: 17010102
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg G. biloba + 100 mg cilostazol
Trial: 17010102
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg G. biloba + 75 mg clopidogrel
Trial: 17010102
Drug: G. biloba
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G. biloba
Trial: 17010102
Drug: Individual doses
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual doses of cilostazol or clopidogrel
Trial: 16216721
Drug: Virgin argan
RxNorm normalized name: argan oil
DrugBank: Argan oil (DB14310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virgin argan oil (VAO) 25 ml/day
Trial: 16216721
Drug: Extra virgin
RxNorm normalized name: Jarrow Formulas Extra Virgin Coconut Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra virgin olive oil (EVO) 25 ml/day
Trial: 12670060
Drug: Donepezil 5
RxNorm normalized name: donepezil 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 5 mg/day for 28 days, then 10 mg/day thereafter
Trial: 7554703
Drug: Physostigmine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine (2 to 12 mg/day)
Trial: 7554703
Drug: Sustained low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sustained low-dose steady-state intravenous infusion of physostigmine (0.5 to 25 mg/day)
Trial: 7554703
Drug: Single high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single high-dose physostigmine (1 to 1.5 mg for 45 to 60 minutes)